Articles tagged "Tolerance"

2018 American Transplant Congress
Relationship between Mixed Chimerism and Acceptance of HLA-Matched and Mismatched Kidney Transplants after Withdrawal of Immunosuppressive Drugs
J. Scandling, S. Busque, R. Lowsky, J. Shizuru, K. Jensen, A. Shori, E. Engleman, E. Meyer, R. Hoppe, S. Strober.
Stanford University, Stanford, CA.
Classical studies in cattle and rodents showed that mixed chimerism (MXC) established in fetuses and neonates was permanent, linked to immune tolerance and graft acceptance…
2018 American Transplant Congress
Tomotherapy and Donor Hematopoietic Cells for Tolerance to Kidney Transplants in Rhesus Macaques
D. Kaufman,¹ L. Haynes,¹ P. Hematti,¹ W. Burlingham,¹ L. Forest,² J. Post,¹ R. Redfield,¹ L. Fernandez,¹ A. D'Alessandro,¹ J. Haynes,¹ K. Jensen,³ S. Strober.³
¹Surgery, University of Wisconsin School of Medicine, Madison, WI; ²Surgical Sciences, University of Wisconsin School of Vet Med, Madison, WI; ³Medicine, Stanford University Medical School, Palo Alto, CA.
The goal of this project was to develop a tolerance induction protocol for MHC 1-haplotype mismatched kidney transplants (txs) in a rhesus macaque model. The…
2018 American Transplant Congress
Renal Allograft Molecular Pathways Associated with Tolerance Induction in Renal Transplantation
L. Gallon,¹ J. Mathew,¹ S. Bontha,² C. Dumur,² P. Dalal,¹ L. Nadimpalli,¹ D. Maluf,² A. Shetty,¹ S. Ildstad,³ J. Leventhal,¹ V. Mas.²
¹Department of Medicine-Nephrology, Northwestern University, Chicago, IL; ²Department of Surgery, University of Virginia, Charlottesville, VA; ³Departments of Surgery, Physiology and Immunology, University of Louisville, Louisville, KY.
Background: Chronic exposure to immunosuppressive agents for organ transplant results in graft nephrotoxicity, infections and malignancies We have established durable immune tolerance in mismatched related…
2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
J. Fung,¹ F. Saliba,¹ H. Schlitt,¹ G. Junge,² K. McCague,³ D. Patel,³ M. Charlton.¹
¹H2304 Study Group, Chicago; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…
2018 American Transplant Congress
Enhancement of Muscle Regeneration and Function via Transplantation of Human Dystrophin Expressing Chimeric Cells as a Novel Myoblast Stem-Cell Based Therapy
M. Siemionow,¹ J. Cwykiel,¹ E. Marchese,¹ G. Rafidi,¹ K. Futoma,¹ A. Heydemann,² J. Garcia-Martinez,² E. Szilagyi.¹
¹Orthopaedics, University of Illinois at Chicago, Chicago; ²Physiology and Biophysics, University of Illinois at Chicago, Chicago.
PURPOSE: Allogeneic myogenic stem cell transplantation aims to restore muscle tissue after traumatic loss or to treat muscular dystrophies. Limited engraftment due to allogeneic rejection…
2018 American Transplant Congress
CD4⁺ T Cells Are Key Barriers to Tolerance Resistance to Islet Allografts in Autoimmune NOD Mice
A. Burrack,¹ K. Beard,² M. Coulombe,² R. Gill.²
¹Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN; ²Surgery, University of Colorado Denver, Aurora, CO.
Pancreatic islet allografts are effective for restoring euglycemia in type 1 diabetics (T1D) but are vulnerable to rejection by autoreactive (islet-specific) and/or conventional alloreactive T…
2018 American Transplant Congress
Long-Term Follow-Up of a Phase 2 Clinical Trial to Induce Tolerance in Living Donor Renal Transplant Recipients
J. Leventhal,¹ J. Galvin,¹ J. Mathew,¹ L. Gallon,¹ D. Stare,¹ K. Kurtenbach,¹ K. Ravindra,³ M. Horwitz,³ J. Miller,¹ M. Abecassis,¹ S. Ildstad.²
¹Surgery, Northwestern U, Chicago; ²U of Louisville, Louisville; ³Duke U, Durham.
37 pts have been transplanted in a phase 2 protocol to induce tolerance in recipients of living donor renal allografts (KTx). The protocol is based…
2018 American Transplant Congress
Achieving Allograft Tolerance through Antigen-Specific Regulatory B Cells
C. Rickert,^1,2 S. Kimura,^1,2 L. Kojima,¹ K. Lee,¹ M. Aburawi,¹ F. Fontan,¹ K. Deng,¹ H. Yeh,^1,2 J. Markmann.^1,2
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA; ²Transplantation Unit, Department of Surgery, Massachusetts General Hospital, Boston, MA.
IntroductionA complete understanding of the role of antigen-specificity in the development of B cell mediated allograft tolerance has remained elusive. Previous work in our lab…
2018 American Transplant Congress
Vendor-Specific Differences in Identical Strains of Mice Yield Dichotomous Result in Lung Allograft Rejection
Y. Guo, Q. Wang, O. Onyema, A. Gelman, D. Kreisel, A. Krupnick.
Surgery, University of Virginina, Charlottesville, VA; Surgery, Washington University in St. Louis, St. Louis, MO.
Intro: Orthotropic transplantation of murine lung allografts has paved the way for mechanistic studies of pulmonary tolerance and rejection but discrepancies have been reported by…
2018 American Transplant Congress
Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study
F. Shihab,¹ Y. Qazi,¹ V. Peddi,¹ D. Shaffer,¹ K. McCague,² D. Patel,² S. Mulgaonkar.¹
¹US92 Study Group, Salt Lake City; ²Novartis Pharmaceutical Corporation, East Hanover.
Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…